ArticleTargeted oncology2016

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Evelyn Despierre et al.PubMed ↗Publisher ↗

No numbers read from the abstract.